Assembly Biosciences, Inc. (NASDAQ:ASMB) – Equities research analysts at William Blair boosted their FY2017 EPS estimates for Assembly Biosciences in a report released on Monday. William Blair analyst Y. Xu now anticipates that the biopharmaceutical company will earn ($2.95) per share for the year, up from their previous forecast of ($3.40). William Blair also issued estimates for Assembly Biosciences’ Q4 2017 earnings at ($0.66) EPS, FY2018 earnings at ($3.18) EPS and FY2019 earnings at ($3.55) EPS.
Several other research firms also recently issued reports on ASMB. BidaskClub raised Assembly Biosciences from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. Jefferies Group LLC initiated coverage on Assembly Biosciences in a research note on Wednesday, November 8th. They set a “buy” rating and a $50.00 price target for the company. Zacks Investment Research downgraded Assembly Biosciences from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. Finally, Chardan Capital reaffirmed a “buy” rating on shares of Assembly Biosciences in a research note on Sunday, September 17th.
Assembly Biosciences (ASMB) opened at $33.06 on Wednesday. Assembly Biosciences has a one year low of $11.07 and a one year high of $36.31.
In related news, Director William R. Ringo sold 1,000 shares of Assembly Biosciences stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $29.55, for a total transaction of $29,550.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 19.60% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the stock. Lyon Street Capital LLC increased its position in Assembly Biosciences by 9.7% during the 3rd quarter. Lyon Street Capital LLC now owns 149,443 shares of the biopharmaceutical company’s stock worth $5,219,000 after purchasing an additional 13,243 shares in the last quarter. Mackenzie Financial Corp purchased a new stake in Assembly Biosciences during the 3rd quarter worth about $577,000. OxFORD Asset Management LLP increased its position in Assembly Biosciences by 26.6% during the 3rd quarter. OxFORD Asset Management LLP now owns 66,227 shares of the biopharmaceutical company’s stock worth $2,220,000 after purchasing an additional 13,925 shares in the last quarter. Wells Fargo & Company MN increased its position in Assembly Biosciences by 148.5% during the 3rd quarter. Wells Fargo & Company MN now owns 25,600 shares of the biopharmaceutical company’s stock worth $894,000 after purchasing an additional 15,300 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its position in Assembly Biosciences by 6.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 177,312 shares of the biopharmaceutical company’s stock worth $5,944,000 after purchasing an additional 11,412 shares in the last quarter. Hedge funds and other institutional investors own 62.19% of the company’s stock.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
Receive News & Ratings for Assembly Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.